Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Drug Therapy 3Cyclophosphamide 3spartalizumab 2fludarabine 2Sirolimus 2Riluzole 2Oncolytic Virotherapy 2Ipilimumab 2Blood Specimen Collection 2vofatamab 1tocilizumab 1saracatinib 1poly ICLC 1pertuzumab 1pazopanib 1liposomal doxorubicin 1ixabepilone 1fludarabine phosphate 1enzalutamide 1durvalumab 1cediranib 1brodalumab 1atezolizumab 1aldesleukin 1advexin 1Ultrasonography 1Tissue Banks 1TKM-080301 1Ritonavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × C188-9 compound × Breast × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡